Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 10/2008

01-10-2008 | Gastrointestinal Oncology

Chemotherapy With Bevacizumab Does Not Affect Liver Regeneration After Portal Vein Embolization in the Treatment of Colorectal Liver Metastases

Authors: Daria Zorzi, MD, Yun Shin Chun, MD, David C. Madoff, MD, Eddie K. Abdalla, MD, Jean-Nicolas Vauthey, MD

Published in: Annals of Surgical Oncology | Issue 10/2008

Login to get access

Abstract

Background

Blockage of vascular endothelial growth factor (VEGF) in murine models has been shown to impair liver regeneration after partial hepatectomy. The aim of this study was to evaluate the effects of chemotherapy with or without bevacizumab (monoclonal antibody anti-VEGF) on liver regeneration after portal vein embolization (PVE) in the treatment of colorectal liver metastases and its possible effect on postoperative outcome after major liver resection.

Methods

Records of 65 consecutive patients treated with or without preoperative chemotherapy (with or without bevacizumab) and PVE for colorectal liver metastases from September 1995 to February 2007 were reviewed from a prospective database. Future liver remnant (FLR) volume, degree of FLR hypertrophy after PVE, morbidity, mortality, and survival were analyzed.

Results

Preoperative PVE was performed after chemotherapy in 43 patients and without chemotherapy in 22 patients. Among the 43 patients treated with chemotherapy, 26 received concurrent bevacizumab. After a median of 4 weeks after PVE, there was no difference in FLR volume increase among patients treated with or without chemotherapy. Similarly, there was no statistically significant difference in degree of FLR hypertrophy among patients treated without (mean, 10.1%) or with chemotherapy, with or without bevacizumab (8.8% and 6.8%) (P = .11). Forty-eight (74%) of 65 patients underwent extended right or right hepatectomy after PVE. No differences in morbidity and mortality were observed among patients treated with or without preoperative chemotherapy (with or without bevacizumab).

Conclusion

Preoperative chemotherapy with bevacizumab does not impair liver regeneration after PVE. Liver resection can be performed safely in patients treated with bevacizumab before PVE.
Literature
1.
Gerber HP, Ferrara N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res 2005; 65:671–80PubMed
2.
Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005; 23:1011–27PubMedCrossRef
3.
Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335–42PubMedCrossRef
4.
Shimizu H, Miyazaki M, Wakabayashi Y, et al. Vascular endothelial growth factor secreted by replicating hepatocytes induces sinusoidal endothelial cell proliferation during regeneration after partial hepatectomy in rats. J Hepatol 2001; 34:683–9PubMedCrossRef
5.
Bockhorn M, Goralski M, Prokofiev D, et al. VEGF is important for early liver regeneration after partial hepatectomy. J Surg Res 2007; 138:291–9PubMedCrossRef
6.
Bowling WM, Kennedy SC, Cai SR, et al. Portal branch occlusion safely facilitates in vivo retroviral vector transduction of rat liver. Hum Gene Ther 1996; 7:2113–21PubMedCrossRef
7.
Duncan JR, Hicks ME, Cai SR, et al. Embolization of portal vein branches induces hepatocyte replication in swine: a potential step in hepatic gene therapy. Radiology 1999; 210:467–77PubMed
8.
Madoff DC, Hicks ME, Abdalla EK, et al. Portal vein embolization with polyvinyl alcohol particles and coils in preparation for major liver resection for hepatobiliary malignancy: safety and effectiveness—study in 26 patients. Radiology 2003; 227:251–60PubMedCrossRef
9.
Madoff DC, Abdalla EK, Gupta S, et al. Transhepatic ipsilateral right portal vein embolization extended to segment IV: improving hypertrophy and resection outcomes with spherical particles and coils. J Vasc Interv Radiol 2005; 16:215–25PubMed
10.
Azoulay D, Castaing D, Krissat J, et al. Percutaneous portal vein embolization increases the feasibility and safety of major liver resection for hepatocellular carcinoma in injured liver. Ann Surg 2000; 232:665–72PubMedCrossRef
11.
Vauthey JN, Madoff DC, Abdalla EK (2007) Preoperative portal vein embolization—a Western perspective. In: Blumgart LH, Belghiti J, Jarnigan WR, et al. (eds). Surgery of the liver, biliary tract, and pancreas. Saunders-Elsevier, Philadelphia, pp 1461–77
12.
Abdalla EK, Hicks ME, Vauthey JN. Portal vein embolization: rationale, technique and future prospects. Br J Surg 2001; 88:165–75PubMedCrossRef
13.
Vauthey JN, Chaoui A, Do KA, et al. Standardized measurement of the future liver remnant prior to extended liver resection: methodology and clinical associations. Surgery 2000; 127:512–29PubMedCrossRef
14.
Vauthey JN, Abdalla EK, Doherty DA, et al. Body surface area and body weight predict total liver volume in Western adults. Liver Transpl 2002; 8:233–40PubMedCrossRef
15.
Johnson TN, Tucker GT, Tanner MS, et al. Changes in liver volume from birth to adulthood: a meta-analysis. Liver Transpl 2005; 11:1481–93PubMedCrossRef
16.
Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 2004; 240:205–13PubMedCrossRef
17.
Vauthey JN, Pawlik TM, Abdalla EK, et al. Is extended hepatectomy for hepatobiliary malignancy justified? Ann Surg 2004; 239:722–32PubMedCrossRef
18.
Shoup M, Gonen M, D’Angelica M, et al. Volumetric analysis predicts hepatic dysfunction in patients undergoing major liver resection. J Gastrointest Surg 2003; 7:325–30PubMedCrossRef
19.
Mullen JT, Ribero D, Reddy SK, et al. Hepatic insufficiency and mortality in 1,059 noncirrhotic patients undergoing major hepatectomy. J Am Coll Surg 2007; 204:854–62PubMedCrossRef
20.
D’Angelica M, Kornprat P, Gonen M, et al. Lack of evidence for increased operative morbidity after hepatectomy with perioperative use of bevacizumab: a matched case-control study. Ann Surg Oncol 2007; 14:759–65PubMedCrossRef
21.
Ribero D, Wang H, Donadon M, et al. Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases. Cancer 2007; 110:2761–7PubMedCrossRef
22.
Reddy SK, Morse MA, Hurwitz HI, et al. Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases. J Am Coll Surg 2008; 206:96–106PubMedCrossRef
23.
Drixler TA, Vogten MJ, Ritchie ED, et al. Liver regeneration is an angiogenesis- associated phenomenon. Ann Surg 2002; 236:703–11PubMedCrossRef
24.
Ellis LM, Curley SA, Grothey A. Surgical resection after downsizing of colorectal liver metastasis in the era of bevacizumab. J Clin Oncol 2005; 23:4853–5PubMedCrossRef
25.
Covey AM, Brown KT, Jarnagin WR, et al. Combined portal vein embolization and neoadjuvant chemotherapy as a treatment strategy for resectable hepatic colorectal metastases. Ann Surg 2008; 247:451–5PubMedCrossRef
26.
Ribero D, Abdalla EK, Madoff DC, et al. Portal vein embolization before major hepatectomy and its effects on regeneration, resectability and outcome. Br J Surg 2007; 94:1386–94PubMedCrossRef
27.
Scappaticci FA, Fehrenbacher L, Cartwright T, et al. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol 2005; 91:173–80PubMedCrossRef
28.
Vauthey JN, Pawlik TM, Ribero D, et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 2006; 24:2065–72PubMedCrossRef
29.
Rubbia-Brandt L, Audard V, Sartoretti P, et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol 2004; 15:460–6PubMedCrossRef
30.
Karoui M, Penna C, Amin-Hashem M, et al. Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases. Ann Surg 2006; 243:1–7PubMedCrossRef
31.
Aloia T, Sebagh M, Plasse M, et al. Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases. J Clin Oncol 2006; 24:4983–90PubMedCrossRef
32.
Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22:696–99.PubMedCrossRef
Metadata
Title
Chemotherapy With Bevacizumab Does Not Affect Liver Regeneration After Portal Vein Embolization in the Treatment of Colorectal Liver Metastases
Authors
Daria Zorzi, MD
Yun Shin Chun, MD
David C. Madoff, MD
Eddie K. Abdalla, MD
Jean-Nicolas Vauthey, MD
Publication date
01-10-2008
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 10/2008
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-008-0035-7

Other articles of this Issue 10/2008

Annals of Surgical Oncology 10/2008 Go to the issue

Hepatic and Pancreatic Tumors

Influence of Hepatic Resection Margin on Recurrence and Survival in Intrahepatic Cholangiocarcinoma

Gastrointestinal Oncology

Barrett’s Esophagus (BE) and Carcinoma in the Esophageal Stump (ES) After Esophagectomy with Gastric Pull-Up in Achalasia Patients: A Study Based on 10 Years Follow-Up

Gastrointestinal Oncology

Targeting VEGF, EGFR, and Other Interacting Pathways for Gastric Cancer—Promises and Reality

Gastrointestinal Oncology

An Interval >7 Weeks between Neoadjuvant Therapy and Surgery Improves Pathologic Complete Response and Disease–Free Survival in Patients with Locally Advanced Rectal Cancer

Bone and Soft Tissue Sarcomas

Staging of Soft Tissue Sarcoma: What Is New?

Melanomas

Validation of a Nomogram to Predict the Presence of Sentinel Lymph Node Metastases in Melanoma